Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis

Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet infectious diseases Vol. 12; no. 6; pp. 449 - 456
Main Authors:	Ettehad, Dena, Schaaf, H Simon, Seddon, James A, Cooke, Graham S, Ford, Nathan
Format:	Journal Article
Language:	English
Published:	London Elsevier Ltd 01.06.2012 Lancet Publishing Group Elsevier Limited
Subjects:	Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Bacterial diseases Biological and medical sciences Child Children Drug resistance Hearing loss Human bacterial diseases Humans Hypothyroidism Infectious Disease Infectious diseases Medical sciences Mycobacterium Nausea Pediatrics Public health Reviews Time Factors Treatment Outcome Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Multidrug-Resistant - drug therapy Vomiting Human Infection Prognosis Treatment Tuberculosis Multiple resistance Bacteriosis Mycobacterial infection Child Bibliographic review
ISSN:	1473-3099, 1474-4457, 1474-4457
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children. We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion. We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54–90·80). Across all studies, 5·9% (95% CI 1·3–10·5) died, 6·2% (2·3–10·2) defaulted, and 39·1% (28·7–49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism. The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available. None.
AbstractList	Summary Background Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children. Methods We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion. Results We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54–90·80). Across all studies, 5·9% (95% CI 1·3–10·5) died, 6·2% (2·3–10·2) defaulted, and 39·1% (28·7–49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism. Interpretation The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available. Funding None. Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children. We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion. We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54–90·80). Across all studies, 5·9% (95% CI 1·3–10·5) died, 6·2% (2·3–10·2) defaulted, and 39·1% (28·7–49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism. The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available. None. Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children.BACKGROUNDPaediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children.We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion.METHODSWe did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion.We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54-90·80). Across all studies, 5·9% (95% CI 1·3-10·5) died, 6·2% (2·3-10·2) defaulted, and 39·1% (28·7-49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism.RESULTSWe identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54-90·80). Across all studies, 5·9% (95% CI 1·3-10·5) died, 6·2% (2·3-10·2) defaulted, and 39·1% (28·7-49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism.The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available.INTERPRETATIONThe treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available.None.FUNDINGNone. Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children. Methods: We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged aO16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion. Results: We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81ADT67% (95% CI 72ADT54a90ADT80). Across all studies, 5ADT9% (95% CI 1ADT3a10ADT5) died, 6ADT2% (2ADT3a10ADT2) defaulted, and 39ADT1% (28ADT7a49ADT4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism. Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children. We did a systematic review and meta-analysis of published and unpublished studies reporting treatment outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. Eligible studies included five or more children (aged ≤16 years) with MDR tuberculosis within a defined treatment cohort. The primary outcome was treatment success, defined as a composite of cure and treatment completion. We identified eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54-90·80). Across all studies, 5·9% (95% CI 1·3-10·5) died, 6·2% (2·3-10·2) defaulted, and 39·1% (28·7-49·4) had an adverse event. The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing loss, psychiatric effects, and hypothyroidism. The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to report outcomes in children to improve the knowledge base for care, especially as new drugs become available. None.
Author	Schaaf, H Simon Ettehad, Dena Seddon, James A Cooke, Graham S Ford, Nathan
Author_xml	– sequence: 1 givenname: Dena surname: Ettehad fullname: Ettehad, Dena organization: Faculty of Medicine, Imperial College London, UK – sequence: 2 givenname: H Simon surname: Schaaf fullname: Schaaf, H Simon organization: Desmond Tutu Tuberculosis Centre, Faculty of Health Sciences, Stellenbosch University, South Africa – sequence: 3 givenname: James A surname: Seddon fullname: Seddon, James A organization: Desmond Tutu Tuberculosis Centre, Faculty of Health Sciences, Stellenbosch University, South Africa – sequence: 4 givenname: Graham S surname: Cooke fullname: Cooke, Graham S organization: Faculty of Medicine, Imperial College London, UK – sequence: 5 givenname: Nathan surname: Ford fullname: Ford, Nathan email: nathan.ford@msf.org organization: Médecins Sans Frontières, Geneva, Switzerland
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25935755$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22373593$$D View this record in MEDLINE/PubMed
BookMark	eNqNkltrFDEUgAep2Iv-BCUgQn0YzWWS7ChVpHiDgg_W55BNztjUTFKTTMv-e7M7q4UFaZ8SDt_5knM5bPZCDNA0Twl-RTARr7-TTrKW4b4_JvSlxJixVjxoDmq4a7uOy73NfUb2m8OcLzEmkuDuUbNPKZOM9-yg8ecJdBkhFBSnYuIIGQ0xIXPhvE0Q0I0rF2icfHE2TT_bBNnloitepiUkM_lYA2-QRnmVC4y6OIMSXDu4QTpYNELRrQ7aryr2uHk4aJ_hyfY8an58-nh--qU9-_b56-mHs9ZwwUsrwDCxIIwA6yjrYSDUdEugggvCmRbaUrPgRsAAnRmosHJp2cLgHrimA7XsqDmevVcp_p4gFzW6bMB7HSBOWRHMFrznosf3QIkUlDApK_p8B72MU6qlbajqIgTTSj3bUtNyBKuukht1Wqm_La_Aiy2gs9F-SDoYl2-5ynDJeeX4zJkUc04w_EMIXj8o1GYF1Hq-ilC1WQElat7bnTzjSh1LDCVp5-_Mfj9nQ51PnWJS2TgIBqxLYIqy0d1peLdjMN4FV0v9BSvItz1TmSo8S9YOQjeGteDk_4J7fOAPvgzyZA
CODEN	LANCAO
CitedBy_id	crossref_primary_10_1186_s13063_018_3070_0 crossref_primary_10_1007_s00112_013_2964_x crossref_primary_10_1016_S1473_3099_16_30474_1 crossref_primary_10_1093_cid_cis1008 crossref_primary_10_1097_INF_0000000000001983 crossref_primary_10_1016_j_pneumo_2014_03_006 crossref_primary_10_1017_S0950268819000049 crossref_primary_10_1183_09031936_00175812 crossref_primary_10_1016_j_mib_2012_07_005 crossref_primary_10_1177_2333794X17744140 crossref_primary_10_1183_09031936_00133613 crossref_primary_10_1055_s_0042_1754318 crossref_primary_10_1016_j_ijid_2020_03_064 crossref_primary_10_1186_s41479_016_0019_5 crossref_primary_10_1371_journal_pone_0203749 crossref_primary_10_2217_cpr_12_62 crossref_primary_10_1186_s13643_022_02023_1 crossref_primary_10_3389_fped_2019_00159 crossref_primary_10_1080_24694193_2017_1386974 crossref_primary_10_1097_INF_0b013e318269cc6a crossref_primary_10_1371_journal_pone_0229284 crossref_primary_10_1007_s00431_012_1811_8 crossref_primary_10_1016_j_jinf_2012_09_002 crossref_primary_10_1371_journal_pone_0037114 crossref_primary_10_1080_14740338_2016_1216544 crossref_primary_10_1097_INF_0000000000002410 crossref_primary_10_1097_INF_0000000000002093 crossref_primary_10_1080_14656566_2017_1373090 crossref_primary_10_1002_jcph_1133 crossref_primary_10_1016_S0140_6736_14_60489_X crossref_primary_10_1164_rccm_201206_1001CI crossref_primary_10_1016_j_tube_2015_02_037 crossref_primary_10_1164_rccm_201606_1227CI crossref_primary_10_58838_2075_1230_2023_101_6_20_27 crossref_primary_10_1080_1120009X_2019_1598039 crossref_primary_10_1001_jamanetworkopen_2022_16527 crossref_primary_10_1371_journal_pmed_1002591 crossref_primary_10_1097_INF_0000000000000369 crossref_primary_10_1183_13993003_00354_2016 crossref_primary_10_1016_S0163_4453_17_30203_7 crossref_primary_10_1097_INF_0000000000001691 crossref_primary_10_1183_13993003_00146_2017 crossref_primary_10_1007_s12098_018_02846_8 crossref_primary_10_1186_1752_1505_8_25 crossref_primary_10_1093_cid_cix561 crossref_primary_10_1016_j_rmcr_2021_101544 crossref_primary_10_1038_s41598_018_23344_z crossref_primary_10_1007_s40506_014_0035_z crossref_primary_10_1007_s40264_015_0267_y crossref_primary_10_1093_cid_cit655 crossref_primary_10_1183_09059180_00005314 crossref_primary_10_1007_s11908_013_0363_z crossref_primary_10_1155_2014_689852 crossref_primary_10_1183_13993003_01289_2016 crossref_primary_10_1128_aac_02144_21 crossref_primary_10_1093_cid_ciw489 crossref_primary_10_1097_QCO_0000000000000062 crossref_primary_10_1016_j_tube_2015_09_007 crossref_primary_10_1080_17512433_2023_2148653 crossref_primary_10_1016_S0140_6736_14_60195_1 crossref_primary_10_58838_2075_1230_2023_101_5_69_76 crossref_primary_10_1080_16549716_2017_1290317 crossref_primary_10_1111_jpc_12503 crossref_primary_10_2147_IDR_S277222 crossref_primary_10_3389_fcimb_2023_1183597 crossref_primary_10_3390_children9081120 crossref_primary_10_1007_s40124_016_0100_9 crossref_primary_10_4103_ijmr_IJMR_1048_18 crossref_primary_10_1097_INF_0000000000003690 crossref_primary_10_1155_2013_756152 crossref_primary_10_1542_peds_2016_2706 crossref_primary_10_1002_cpt_175 crossref_primary_10_1371_journal_pone_0230504 crossref_primary_10_1186_s13643_017_0407_9 crossref_primary_10_1016_j_tube_2013_10_003 crossref_primary_10_1371_journal_pone_0227100 crossref_primary_10_1007_s00431_023_05167_x crossref_primary_10_5812_pedinfect_17934 crossref_primary_10_1016_j_pcl_2021_09_004 crossref_primary_10_1016_j_ijid_2016_11_423 crossref_primary_10_1016_S2213_2600_14_70009_8 crossref_primary_10_1007_s10405_014_0779_7 crossref_primary_10_1183_09031936_00188313 crossref_primary_10_1016_j_phrs_2016_01_020 crossref_primary_10_1183_09031936_00179712 crossref_primary_10_1016_j_cmi_2016_10_008 crossref_primary_10_1080_14740338_2016_1223623 crossref_primary_10_1016_S1473_3099_12_70038_5 crossref_primary_10_1186_s12889_021_10173_5 crossref_primary_10_1093_jpids_pit012 crossref_primary_10_1183_13993003_00353_2018 crossref_primary_10_1186_s12879_016_1524_0 crossref_primary_10_1057_jphp_2014_35 crossref_primary_10_1016_j_pneumo_2014_05_001 crossref_primary_10_1179_1973947813Y_0000000105 crossref_primary_10_1136_thoraxjnl_2013_203900 crossref_primary_10_1186_s41479_016_0018_6 crossref_primary_10_1186_s13104_018_3148_5 crossref_primary_10_1016_S2213_2600_17_30079_6 crossref_primary_10_18410_jebmh_2018_297 crossref_primary_10_1183_16000617_0107_2018 crossref_primary_10_1164_rccm_201909_1874ST crossref_primary_10_1016_j_ijid_2021_06_022 crossref_primary_10_1016_S1473_3099_13_70030_6 crossref_primary_10_31616_asj_2017_0217 crossref_primary_10_7861_clinmedicine_14_3_279 crossref_primary_10_1007_s12519_013_0404_6 crossref_primary_10_1093_cid_civ582 crossref_primary_10_3201_eid2111_151119 crossref_primary_10_1186_1471_2334_14_11 crossref_primary_10_1542_pir_2018_0093
Cites_doi	10.1186/1471-2288-8-79 10.1016/S1473-3099(10)70139-0 10.1093/cid/cir772 10.1136/adc.88.12.1106 10.1097/INF.0b013e3181783aca 10.1371/journal.pone.0006914 10.1097/INF.0b013e31820b583d 10.1002/sim.4780142408 10.1001/jama.293.22.2732 10.1097/INF.0b013e31819bc491 10.1183/09031936.00073611 10.1371/journal.pmed.0040292 10.1016/S0031-3955(16)38979-9 10.1097/01.inf.0000199314.88063.4c 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I 10.1016/j.prrv.2010.09.010 10.1136/adc.2008.139543 10.1183/09031936.98.11051116 10.1183/09031936.00186310 10.1016/S1473-3099(09)70041-6 10.1016/S1473-3099(11)70167-0 10.1097/MCP.0b013e3280f3c0b2 10.1186/1471-2334-11-28 10.1136/bmj.c221 10.1371/journal.pmed.1001026 10.1542/peds.109.5.765 10.1371/journal.pmed.0050004 10.1542/peds.2005-2235
ContentType	Journal Article
Copyright	2012 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2012 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jun 2012
Copyright_xml	– notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jun 2012
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8
DOI	10.1016/S1473-3099(12)70033-6
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Bacteriology Abstracts (Microbiology B) ProQuest One Academic Middle East (New) MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	1474-4457
EndPage	456
ExternalDocumentID	2680466271 22373593 25935755 10_1016_S1473_3099_12_70033_6 S1473309912700336 1_s2_0_S1473309912700336
Genre	Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article
GrantInformation	None.
GroupedDBID	--- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R ~HD 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AJBFU ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI 7X8
ID	FETCH-LOGICAL-c565t-6ec368131e34239ef12c4be2656153a6ad2c85c6efe4cf26d7bd38c09e5a2f2d3
IEDL.DBID	7RV
ISICitedReferencesCount	121
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000304789300017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1473-3099 1474-4457
IngestDate	Mon Oct 06 17:48:31 EDT 2025 Sun Nov 09 12:25:17 EST 2025 Mon Oct 06 18:22:38 EDT 2025 Mon Jul 21 05:31:39 EDT 2025 Mon Jul 21 09:14:14 EDT 2025 Sat Nov 29 07:03:19 EST 2025 Tue Nov 18 22:26:00 EST 2025 Fri Feb 23 02:27:00 EST 2024 Sun Feb 23 10:19:07 EST 2025 Tue Oct 14 19:31:08 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	Human Infection Prognosis Treatment Tuberculosis Multiple resistance Bacteriosis Mycobacterial infection Child Bibliographic review
Language	English
License	CC BY 4.0 Copyright © 2012 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c565t-6ec368131e34239ef12c4be2656153a6ad2c85c6efe4cf26d7bd38c09e5a2f2d3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 ObjectType-Feature-1
PMID	22373593
PQID	1019031102
PQPubID	44001
PageCount	8
ParticipantIDs	proquest_miscellaneous_1038595690 proquest_miscellaneous_1017621377 proquest_journals_1019031102 pubmed_primary_22373593 pascalfrancis_primary_25935755 crossref_primary_10_1016_S1473_3099_12_70033_6 crossref_citationtrail_10_1016_S1473_3099_12_70033_6 elsevier_sciencedirect_doi_10_1016_S1473_3099_12_70033_6 elsevier_clinicalkeyesjournals_1_s2_0_S1473309912700336 elsevier_clinicalkey_doi_10_1016_S1473_3099_12_70033_6
PublicationCentury	2000
PublicationDate	2012-06-01
PublicationDateYYYYMMDD	2012-06-01
PublicationDate_xml	– month: 06 year: 2012 text: 2012-06-01 day: 01
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: United States
PublicationTitle	The Lancet infectious diseases
PublicationTitleAlternate	Lancet Infect Dis
PublicationYear	2012
Publisher	Elsevier Ltd Lancet Publishing Group Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Lancet Publishing Group – name: Elsevier Limited
References	Houwert, Borggreven, Schaaf, Nel, Donald, Stolk (bib5) 1998; 11 Furin, Mitnick, Shin (bib28) 2001; 5 Munsiff, Ahuja, Li, Driver (bib40) 2006; 10 Swanson, Starke (bib27) 1995; 42 Schaaf (bib4) 2007; 97 Schaaf, Shean, Donald (bib7) 2003; 88 Granich, Oh, Lewis, Porco, Flood (bib23) 2005; 293 Schaaf, Gie, Kennedy, Beyers, Hesseling, Donald (bib33) 2002; 109 Golder, Loke, Bland (bib38) 2011; 8 Smith, Spiegelhalter, Thomas (bib18) 1995; 14 Al-Dabbagh, Lapphra, McGloin (bib31) 2011; 30 Schaaf, Marais (bib30) 2011; 12 Mendez Echevarria, Baquero Artigao, Garcia Miguel (bib21) 2007; 67 Guyatt, Mills, Elbourne (bib37) 2008; 5 Sandgren A, Cuevas LE, Dara M, et al. Childhood tuberculosis: progress requires advocacy strategy now. Schaaf HS, Seddon J, Rautenbach C, Hesseling AC. Fourth serial 2-year tuberculosis drug resistance survey in children, Western Cape, South Africa. 42nd world conference on lung health of the international union against tuberculosis and lung disease (The Union); Lille; Oct 26–30, 2011. Abstr OP-614-28. Caminero, Sotgiu, Zumla, Migliori (bib13) 2010; 10 Rucker, Schwarzer, Carpenter, Schumacher (bib19) 2008; 8 Seddon, Hesseling, Willemse, Donald, Schaaf (bib24) 2012; 54 Falzon, Jaramillo, Schünemann (bib11) 2011; 38 Leung, Yew, Leung, Leung, Tam (bib32) 2011; 38 Abubakar, Laundy, French, Shingadia (bib39) 2008; 93 (in press). Hesseling, Schaaf, Gie, Starke, Beyers (bib6) 2002; 6 Schaaf, Willemse, Donald (bib8) 2009; 28 Furin (bib14) 2007; 13 Drobac, Mukherjee, Joseph (bib20) 2006; 117 Mitnick, Castro, Harrington, Sacks, Burman (bib12) 2007; 4 Nicol, Workman, Isaacs (bib34) 2011; 11 Riley, Lambert, Abo-Zaid (bib36) 2010; 340 Hesseling, Schaaf, Gie, Starke, Beyers (bib35) 2002; 6 Orenstein, Basu, Shah (bib15) 2009; 9 Feja, McNelley, Tran, Burzynski, Saiman (bib22) 2008; 27 Leimane V, Ozere I. Challenges of managing a child with MDR-TB: 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Cancun, Mexico, 3–7 December 2009. Johnston, Shahidi, Sadatsafavi, Fitzgerald (bib29) 2009; 4 du Cros, Nyangwa, Gale, Venis, Ford (bib41) 2011; 89 Nelson, Wells (bib2) 2004; 8 bib1 Fairlie, Beylis, Reubenson, Moore, Madhi (bib25) 2011; 11 Borenstien, Hedges, Higgins, Rothstein (bib17) 2008 Padayatchi, Bamber, Dawood, Bobat (bib9) 2006; 25 Laserson, Thorpe, Leimane (bib42) 2005; 9 Newcombe (bib16) 1998; 17 10.1016/S1473-3099(12)70033-6_bib26 Mitnick (10.1016/S1473-3099(12)70033-6_bib12) 2007; 4 Swanson (10.1016/S1473-3099(12)70033-6_bib27) 1995; 42 Schaaf (10.1016/S1473-3099(12)70033-6_bib33) 2002; 109 Rucker (10.1016/S1473-3099(12)70033-6_bib19) 2008; 8 Johnston (10.1016/S1473-3099(12)70033-6_bib29) 2009; 4 Hesseling (10.1016/S1473-3099(12)70033-6_bib35) 2002; 6 Riley (10.1016/S1473-3099(12)70033-6_bib36) 2010; 340 Mendez Echevarria (10.1016/S1473-3099(12)70033-6_bib21) 2007; 67 Munsiff (10.1016/S1473-3099(12)70033-6_bib40) 2006; 10 Seddon (10.1016/S1473-3099(12)70033-6_bib24) 2012; 54 Furin (10.1016/S1473-3099(12)70033-6_bib14) 2007; 13 Nicol (10.1016/S1473-3099(12)70033-6_bib34) 2011; 11 du Cros (10.1016/S1473-3099(12)70033-6_bib41) 2011; 89 Smith (10.1016/S1473-3099(12)70033-6_bib18) 1995; 14 Houwert (10.1016/S1473-3099(12)70033-6_bib5) 1998; 11 Guyatt (10.1016/S1473-3099(12)70033-6_bib37) 2008; 5 Hesseling (10.1016/S1473-3099(12)70033-6_bib6) 2002; 6 Al-Dabbagh (10.1016/S1473-3099(12)70033-6_bib31) 2011; 30 Abubakar (10.1016/S1473-3099(12)70033-6_bib39) 2008; 93 Caminero (10.1016/S1473-3099(12)70033-6_bib13) 2010; 10 Leung (10.1016/S1473-3099(12)70033-6_bib32) 2011; 38 Schaaf (10.1016/S1473-3099(12)70033-6_bib4) 2007; 97 Padayatchi (10.1016/S1473-3099(12)70033-6_bib9) 2006; 25 10.1016/S1473-3099(12)70033-6_bib10 10.1016/S1473-3099(12)70033-6_bib3 Fairlie (10.1016/S1473-3099(12)70033-6_bib25) 2011; 11 Orenstein (10.1016/S1473-3099(12)70033-6_bib15) 2009; 9 Drobac (10.1016/S1473-3099(12)70033-6_bib20) 2006; 117 Furin (10.1016/S1473-3099(12)70033-6_bib28) 2001; 5 Feja (10.1016/S1473-3099(12)70033-6_bib22) 2008; 27 Schaaf (10.1016/S1473-3099(12)70033-6_bib30) 2011; 12 Granich (10.1016/S1473-3099(12)70033-6_bib23) 2005; 293 Newcombe (10.1016/S1473-3099(12)70033-6_bib16) 1998; 17 Borenstien (10.1016/S1473-3099(12)70033-6_bib17) 2008 Schaaf (10.1016/S1473-3099(12)70033-6_bib8) 2009; 28 Laserson (10.1016/S1473-3099(12)70033-6_bib42) 2005; 9 Golder (10.1016/S1473-3099(12)70033-6_bib38) 2011; 8 Nelson (10.1016/S1473-3099(12)70033-6_bib2) 2004; 8 Schaaf (10.1016/S1473-3099(12)70033-6_bib7) 2003; 88 Falzon (10.1016/S1473-3099(12)70033-6_bib11) 2011; 38 22373592 - Lancet Infect Dis. 2012 Jun;12(6):425-6. doi: 10.1016/S1473-3099(12)70038-5.
References_xml	– volume: 38 start-page: 516 year: 2011 end-page: 528 ident: bib11 article-title: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update publication-title: Eur Respir J – start-page: 312 year: 2008 ident: bib17 publication-title: Introduction to meta-analysis – reference: Sandgren A, Cuevas LE, Dara M, et al. Childhood tuberculosis: progress requires advocacy strategy now. – volume: 340 start-page: c221 year: 2010 ident: bib36 article-title: Meta-analysis of individual participant data: rationale, conduct, and reporting publication-title: BMJ – volume: 38 start-page: 227 year: 2011 end-page: 230 ident: bib32 article-title: Shorter treatment duration for selected patients with multidrug-resistant tuberculosis publication-title: Eur Respir J – volume: 11 start-page: 28 year: 2011 ident: bib25 article-title: High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study publication-title: BMC Infect Dis – volume: 25 start-page: 147 year: 2006 end-page: 150 ident: bib9 article-title: Multidrug-resistant tuberculous meningitis in children in Durban, South Africa publication-title: Pediatr Infect Dis J – ident: bib1 article-title: Global tuberculosis control: WHO report – volume: 293 start-page: 2732 year: 2005 end-page: 2739 ident: bib23 article-title: Multidrug resistance among persons with tuberculosis in California, 1994–2003 publication-title: JAMA – volume: 11 start-page: 819 year: 2011 end-page: 824 ident: bib34 article-title: Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study publication-title: Lancet Infect Dis – volume: 109 start-page: 765 year: 2002 end-page: 771 ident: bib33 article-title: Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up publication-title: Pediatrics – volume: 42 start-page: 553 year: 1995 end-page: 581 ident: bib27 article-title: Drug-resistant tuberculosis in pediatrics publication-title: Pediatr Clin North Am – volume: 11 start-page: 1116 year: 1998 end-page: 1120 ident: bib5 article-title: Prospective evaluation of World Health Organization criteria to assist diagnosis of tuberculosis in children publication-title: Eur Respir J – reference: Leimane V, Ozere I. Challenges of managing a child with MDR-TB: 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Cancun, Mexico, 3–7 December 2009. – volume: 97 start-page: 995 year: 2007 end-page: 997 ident: bib4 article-title: Drug-resistant tuberculosis in children publication-title: S Afr Med J – volume: 17 start-page: 873 year: 1998 end-page: 890 ident: bib16 article-title: Interval estimation for the difference between independent proportions: comparison of eleven methods publication-title: Stat Med – volume: 14 start-page: 2685 year: 1995 end-page: 2699 ident: bib18 article-title: Bayesian approaches to random-effects meta-analysis: a comparative study publication-title: Stat Med – volume: 6 start-page: 1038 year: 2002 end-page: 1045 ident: bib35 article-title: A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 67 start-page: 206 year: 2007 end-page: 211 ident: bib21 article-title: Multidrug-resistant tuberculosis in the pediatric age group publication-title: An Pediatr (Barc) – volume: 117 start-page: 2022 year: 2006 end-page: 2029 ident: bib20 article-title: Community-based therapy for children with multidrug-resistant tuberculosis publication-title: Pediatrics – volume: 5 start-page: 648 year: 2001 end-page: 655 ident: bib28 article-title: Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 8 start-page: 636 year: 2004 end-page: 647 ident: bib2 article-title: Global epidemiology of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 4 start-page: e292 year: 2007 ident: bib12 article-title: Randomized trials to optimize treatment of multidrug-resistant tuberculosis publication-title: PLoS Med – volume: 30 start-page: 501 year: 2011 end-page: 505 ident: bib31 article-title: Drug-resistant tuberculosis: pediatric guidelines publication-title: Pediatr Infect Dis J – volume: 10 start-page: 639 year: 2006 end-page: 648 ident: bib40 article-title: Public-private collaboration for multidrug-resistant tuberculosis control in New York City publication-title: Int J Tuberc Lung Dis – volume: 28 start-page: 748 year: 2009 end-page: 750 ident: bib8 article-title: Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis publication-title: Pediatr Infect Dis J – volume: 10 start-page: 621 year: 2010 end-page: 629 ident: bib13 article-title: Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis publication-title: Lancet Infect Dis – volume: 5 start-page: e4 year: 2008 ident: bib37 article-title: In the era of systematic reviews, does the size of an individual trial still matter publication-title: PLoS Med – volume: 88 start-page: 1106 year: 2003 end-page: 1111 ident: bib7 article-title: Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome publication-title: Arch Dis Child – volume: 8 start-page: e1001026 year: 2011 ident: bib38 article-title: Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview publication-title: PLoS Med – reference: Schaaf HS, Seddon J, Rautenbach C, Hesseling AC. Fourth serial 2-year tuberculosis drug resistance survey in children, Western Cape, South Africa. 42nd world conference on lung health of the international union against tuberculosis and lung disease (The Union); Lille; Oct 26–30, 2011. Abstr OP-614-28. – volume: 27 start-page: 907 year: 2008 end-page: 912 ident: bib22 article-title: Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003 publication-title: Pediatr Infect Dis J – volume: 4 start-page: e6914 year: 2009 ident: bib29 article-title: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis publication-title: PLoS One – volume: 9 start-page: 640 year: 2005 end-page: 645 ident: bib42 article-title: Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 13 start-page: 212 year: 2007 end-page: 217 ident: bib14 article-title: The clinical management of drug-resistant tuberculosis publication-title: Curr Opin Pulm Med – volume: 6 start-page: 1038 year: 2002 end-page: 1045 ident: bib6 article-title: A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 9 start-page: 153 year: 2009 end-page: 161 ident: bib15 article-title: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis publication-title: Lancet Infect Dis – volume: 93 start-page: 1017 year: 2008 end-page: 1021 ident: bib39 article-title: Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999–2006 publication-title: Arch Dis Child – volume: 54 start-page: 157 year: 2012 end-page: 166 ident: bib24 article-title: Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome publication-title: Clin Infect Dis – volume: 89 start-page: 855 year: 2011 ident: bib41 article-title: Counting children: comparing reporting for paediatric HIV and tuberculosis publication-title: WHO Bulletin – volume: 8 start-page: 79 year: 2008 ident: bib19 article-title: Undue reliance on I (2) in assessing heterogeneity may mislead publication-title: BMC Med Res Methodol – volume: 12 start-page: 31 year: 2011 end-page: 38 ident: bib30 article-title: Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians publication-title: Paediatr Respir Rev – reference: (in press). – volume: 8 start-page: 79 year: 2008 ident: 10.1016/S1473-3099(12)70033-6_bib19 article-title: Undue reliance on I (2) in assessing heterogeneity may mislead publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-8-79 – volume: 9 start-page: 640 year: 2005 ident: 10.1016/S1473-3099(12)70033-6_bib42 article-title: Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – start-page: 312 year: 2008 ident: 10.1016/S1473-3099(12)70033-6_bib17 – volume: 6 start-page: 1038 year: 2002 ident: 10.1016/S1473-3099(12)70033-6_bib6 article-title: A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 10 start-page: 621 year: 2010 ident: 10.1016/S1473-3099(12)70033-6_bib13 article-title: Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(10)70139-0 – volume: 54 start-page: 157 year: 2012 ident: 10.1016/S1473-3099(12)70033-6_bib24 article-title: Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome publication-title: Clin Infect Dis doi: 10.1093/cid/cir772 – volume: 88 start-page: 1106 year: 2003 ident: 10.1016/S1473-3099(12)70033-6_bib7 article-title: Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome publication-title: Arch Dis Child doi: 10.1136/adc.88.12.1106 – volume: 27 start-page: 907 year: 2008 ident: 10.1016/S1473-3099(12)70033-6_bib22 article-title: Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181783aca – volume: 4 start-page: e6914 year: 2009 ident: 10.1016/S1473-3099(12)70033-6_bib29 article-title: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0006914 – volume: 30 start-page: 501 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib31 article-title: Drug-resistant tuberculosis: pediatric guidelines publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31820b583d – volume: 14 start-page: 2685 year: 1995 ident: 10.1016/S1473-3099(12)70033-6_bib18 article-title: Bayesian approaches to random-effects meta-analysis: a comparative study publication-title: Stat Med doi: 10.1002/sim.4780142408 – volume: 5 start-page: 648 year: 2001 ident: 10.1016/S1473-3099(12)70033-6_bib28 article-title: Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 97 start-page: 995 year: 2007 ident: 10.1016/S1473-3099(12)70033-6_bib4 article-title: Drug-resistant tuberculosis in children publication-title: S Afr Med J – volume: 293 start-page: 2732 year: 2005 ident: 10.1016/S1473-3099(12)70033-6_bib23 article-title: Multidrug resistance among persons with tuberculosis in California, 1994–2003 publication-title: JAMA doi: 10.1001/jama.293.22.2732 – volume: 28 start-page: 748 year: 2009 ident: 10.1016/S1473-3099(12)70033-6_bib8 article-title: Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31819bc491 – volume: 38 start-page: 516 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib11 article-title: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update publication-title: Eur Respir J doi: 10.1183/09031936.00073611 – volume: 4 start-page: e292 year: 2007 ident: 10.1016/S1473-3099(12)70033-6_bib12 article-title: Randomized trials to optimize treatment of multidrug-resistant tuberculosis publication-title: PLoS Med doi: 10.1371/journal.pmed.0040292 – volume: 42 start-page: 553 year: 1995 ident: 10.1016/S1473-3099(12)70033-6_bib27 article-title: Drug-resistant tuberculosis in pediatrics publication-title: Pediatr Clin North Am doi: 10.1016/S0031-3955(16)38979-9 – volume: 25 start-page: 147 year: 2006 ident: 10.1016/S1473-3099(12)70033-6_bib9 article-title: Multidrug-resistant tuberculous meningitis in children in Durban, South Africa publication-title: Pediatr Infect Dis J doi: 10.1097/01.inf.0000199314.88063.4c – volume: 17 start-page: 873 year: 1998 ident: 10.1016/S1473-3099(12)70033-6_bib16 article-title: Interval estimation for the difference between independent proportions: comparison of eleven methods publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I – ident: 10.1016/S1473-3099(12)70033-6_bib10 – volume: 10 start-page: 639 year: 2006 ident: 10.1016/S1473-3099(12)70033-6_bib40 article-title: Public-private collaboration for multidrug-resistant tuberculosis control in New York City publication-title: Int J Tuberc Lung Dis – volume: 12 start-page: 31 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib30 article-title: Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians publication-title: Paediatr Respir Rev doi: 10.1016/j.prrv.2010.09.010 – volume: 93 start-page: 1017 year: 2008 ident: 10.1016/S1473-3099(12)70033-6_bib39 article-title: Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999–2006 publication-title: Arch Dis Child doi: 10.1136/adc.2008.139543 – volume: 11 start-page: 1116 year: 1998 ident: 10.1016/S1473-3099(12)70033-6_bib5 article-title: Prospective evaluation of World Health Organization criteria to assist diagnosis of tuberculosis in children publication-title: Eur Respir J doi: 10.1183/09031936.98.11051116 – volume: 38 start-page: 227 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib32 article-title: Shorter treatment duration for selected patients with multidrug-resistant tuberculosis publication-title: Eur Respir J doi: 10.1183/09031936.00186310 – volume: 8 start-page: 636 year: 2004 ident: 10.1016/S1473-3099(12)70033-6_bib2 article-title: Global epidemiology of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – ident: 10.1016/S1473-3099(12)70033-6_bib26 – volume: 9 start-page: 153 year: 2009 ident: 10.1016/S1473-3099(12)70033-6_bib15 article-title: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(09)70041-6 – volume: 11 start-page: 819 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib34 article-title: Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70167-0 – volume: 13 start-page: 212 year: 2007 ident: 10.1016/S1473-3099(12)70033-6_bib14 article-title: The clinical management of drug-resistant tuberculosis publication-title: Curr Opin Pulm Med doi: 10.1097/MCP.0b013e3280f3c0b2 – volume: 11 start-page: 28 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib25 article-title: High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study publication-title: BMC Infect Dis doi: 10.1186/1471-2334-11-28 – volume: 6 start-page: 1038 year: 2002 ident: 10.1016/S1473-3099(12)70033-6_bib35 article-title: A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis publication-title: Int J Tuberc Lung Dis – ident: 10.1016/S1473-3099(12)70033-6_bib3 – volume: 89 start-page: 855 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib41 article-title: Counting children: comparing reporting for paediatric HIV and tuberculosis publication-title: WHO Bulletin – volume: 67 start-page: 206 year: 2007 ident: 10.1016/S1473-3099(12)70033-6_bib21 article-title: Multidrug-resistant tuberculosis in the pediatric age group publication-title: An Pediatr (Barc) – volume: 340 start-page: c221 year: 2010 ident: 10.1016/S1473-3099(12)70033-6_bib36 article-title: Meta-analysis of individual participant data: rationale, conduct, and reporting publication-title: BMJ doi: 10.1136/bmj.c221 – volume: 8 start-page: e1001026 year: 2011 ident: 10.1016/S1473-3099(12)70033-6_bib38 article-title: Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview publication-title: PLoS Med doi: 10.1371/journal.pmed.1001026 – volume: 109 start-page: 765 year: 2002 ident: 10.1016/S1473-3099(12)70033-6_bib33 article-title: Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up publication-title: Pediatrics doi: 10.1542/peds.109.5.765 – volume: 5 start-page: e4 year: 2008 ident: 10.1016/S1473-3099(12)70033-6_bib37 article-title: In the era of systematic reviews, does the size of an individual trial still matter publication-title: PLoS Med doi: 10.1371/journal.pmed.0050004 – volume: 117 start-page: 2022 year: 2006 ident: 10.1016/S1473-3099(12)70033-6_bib20 article-title: Community-based therapy for children with multidrug-resistant tuberculosis publication-title: Pediatrics doi: 10.1542/peds.2005-2235 – reference: 22373592 - Lancet Infect Dis. 2012 Jun;12(6):425-6. doi: 10.1016/S1473-3099(12)70038-5.
SSID	ssj0017104
Score	2.4400966
SecondaryResourceType	review_article
Snippet	Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR... Summary Background Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	449
SubjectTerms	Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Bacterial diseases Biological and medical sciences Child Children Drug resistance Hearing loss Human bacterial diseases Humans Hypothyroidism Infectious Disease Infectious diseases Medical sciences Mycobacterium Nausea Pediatrics Public health Reviews Time Factors Treatment Outcome Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Multidrug-Resistant - drug therapy Vomiting
Title	Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1473309912700336 https://www.clinicalkey.es/playcontent/1-s2.0-S1473309912700336 https://dx.doi.org/10.1016/S1473-3099(12)70033-6 https://www.ncbi.nlm.nih.gov/pubmed/22373593 https://www.proquest.com/docview/1019031102 https://www.proquest.com/docview/1017621377 https://www.proquest.com/docview/1038595690
Volume	12
WOSCitedRecordID	wos000304789300017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7RV dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (subscription) customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: BENPR dateStart: 20010801 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7X7 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 8C1 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagRQip4lFeC2VlJA5wMKztxHG4IKhacWFVlYJ6sxx7gpCW3WWT8PsZ20lWSLRF4uKD45GdeDzzxfMi5IXSDrgsHPO5K1nmqorp3ALzHAQ4CzlXqdhEMZ_r8_PypL9wa3q3ykEmRkHtVy7ckePpRtUlUVmJd-ufLFSNCtbVvoTGdbLLAzZGfi5Ov45WBNSe0aqcFZJJhELbCJ43n8fOl1y8KmJJM3WRbtpb2wa_WJ1KXVyMRaNOOr7zv29zl9zu0Sh9n9jnHrkGy31y81Nvb98ne-lWj6ZgpftkcTb4pdNV1-JU0FBEvXQICafhWpdGJ0W_6b4x_JcP-BSHt10FG9ctVtjxllq6zSBNU_QMtUtPf0Brme3zpDwgX46Pzg4_sr5eA3MIC1umwEmlueQQ0wpCzYXLKhAIGVGuWmW9cDp3CmrIXC2ULyovtZuVkFtRCy8fkp3lagmPCdU5lFyAF34GWS2qSvhSC45jc-F9WUxINuyUcX0y81BTY2FGr7WwwSZssOHCxA02akJej2TrlM3jKgI1sIEZQlVRuBrUN1cRFn8jhKYXEY3hphFmlqgDcXQBkBIp9UjZo6CEbv5l0ukfnDq-I_7jSsTl-YQcDOxotgsZeXFCno-PUcoE05FdwqqLY1BrhuyUl42RIVmeKmcT8igdi-0ChCwkLuLJ5Qt4Sm4hIBXJFe-A7LSbDp6RG-5X-73ZTOPhDu15EVuNrT7kU7L74Wh-cvobyhVWOg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQRSp4lEKLJRiJJDgYFjbiZMgIYSAqlXbFRKLtDfj2BOEtOwumwTEn-I3Mo6TrJBoy6UHroknsZN5fGPPg5BHKrXAZWKZi23GIpvnLI0NMMdBgDUQcxWaTSSjUTqZZO_XyK8uF8aHVXY6sVHUbm79HjlKN5ouicZKvFp8Y75rlD9d7VpoBLY4hJ8_0GUrXx68xf_7WIi9d-M3-6ztKsAsgpeKKbBSpVxyaIrfQcGFjXIQCGxQ-o0yTtg0tgoKiGwhlEtyJ1M7zCA2ohBO4nMvkIuoxxPv7CWT3sHjaK2bU-wokUwi9FplDD3_0F98wsXTpGmhpk6yhZsLU-IfKkJrjZOxb2MD9679b1_vOrnaom36OojHDbIGsy1y-biNJ9gim2HXkoZkrJtkOu7i7um8rnBpUFJE9bRLead-25o2QZhuWX9mSyg9_sbhVZ3D0tbTOV54QQ1dVcimITuImpmjX6EyzLR1YLbJx3NZ-y2yPpvP4A6haQwZF-CEG0JUiDwXLksFx7GxcC5LBiTqOEPbtli77xky1X1Unmco7RlKc6EbhtJqQJ71ZItQreQsAtWxne5ScdF4aLSnZxEmfyOEslWBpea6FHoYqD1xE-IgJVKmPWWL8gJ6-5eX7v4hGf0a0YeX6HfEA7LTsb9eTaTn_QF52N9GLeqPxswM5nUzBlGBr7552hjpiwGqbDggt4MYriYgZCJxEndPn8ADsrE_Pj7SRwejw3vkCoJvEcIOd8h6tazhPrlkv1dfyuVuo1go-XTesvgbJ0-vmA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQNOkicu4FcYwEkjsway2EydBQghtVEyDahJD2ptx7JMJqbSlSUD8NX4dx3GSColtvOyB19SntZtz-Wx_5xxCnqrUApeJZS62GYtsnrM0NsAcBwHWQMxVaDaRjMfpyUl2tEJ-dbkwnlbZ-cTGUbuZ9WfkaN0YuiQGK7FbtLSIo_3R6_k35jtI-ZvWrp1GUJFD-PkDt2_lq4N9fNfPhBi9Pd57x9oOA8wikKmYAitVyiWHphAeFFzYKAeBIAc9gVHGCZvGVkEBkS2EcknuZGqHGcRGFMJJ_N4r5GoilfQbv3Svp5dwjNzNjXaUSCYRhi2zh3Y_9g-fc7GTNO3U1FlxcWNuSnxbRWizcTYObuLh6Mb__E_eJNdbFE7fBLO5RVZguknWPrQ8g02yEU4zaUjSuk0mxx0fn87qCpcJJUW0T7tUeOqPs2lDznSL-pQtoPS4HIdXdQ4LW09m-OAlNXRZOZuGrCFqpo5-hcow09aHuUM-Xcra75LV6WwK9wlNY8i4ACfcEKJC5LlwWSo4jo2Fc1kyIFGnJdq2Rdx9L5GJ7tl6Xrm0Vy7NhW6US6sBedGLzUMVk4sEVKeCukvRxaCiMc5eJJj8TRDK1jWWmutS6GGQ9sIN9UFKlEx7yRb9BVT3Lz-6_YeV9GvEvb3E_Ug8IFudKejlRHo7GJAn_cfoXf2VmZnCrG7GIFrwVTnPGyN9kUCVDQfkXjDJ5QSETCRO4sH5E3hM1tAE9fuD8eFDso6YXAQ24hZZrRY1PCLX7PfqS7nYbnwMJZ8v2xR_A5bZuB8
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+outcomes+for+children+with+multidrug-resistant+tuberculosis%3A+a+systematic+review+and+meta-analysis&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Ettehad%2C+Dena%2C+BSc&rft.au=Schaaf%2C+H+Simon%2C+MD&rft.au=Seddon%2C+James+A%2C+MBBS&rft.au=Cooke%2C+Graham+S%2C+DPhil&rft.date=2012-06-01&rft.issn=1473-3099&rft.volume=12&rft.issue=6&rft.spage=449&rft.epage=456&rft_id=info:doi/10.1016%2FS1473-3099%2812%2970033-6&rft.externalDBID=ECK1-s2.0-S1473309912700336&rft.externalDocID=1_s2_0_S1473309912700336
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14733099%2FS1473309912X70440%2Fcov150h.gif